title: Chemotherapy and serum hyaluronic acid levels in malignant peritoneal mesothelioma.
abstract: We report a case of malignant peritoneal mesothelioma in a 63-year-old man. Right hemicolectomy, partial ileectomy, partial omentectomy, excision of the abdominal wall, and catheterization for intraperitoneal infusion chemotherapy were performed as surgery. Histopathologically, the tumor was composed of papillary and sheet-like proliferation of atypical cells for which an Alcian Blue digestive test with hyaluronidase was positive. By immunohistochemical staining, the tumor cells were stained against HBME-1 and thrombomodulin antibodies. The final diagnosis was a diffuse malignant mesothelioma of the epithelial type. Sequential adjuvant chemotherapies of cisplatin (ip) plus 5-fluorouracil (iv), cisplatin (iv) plus 5-fluorouracil (iv), and mitomycin C (iv) were administered. He is still alive 46 months after surgery. Moreover, the increase in serum hyaluronic acid levels has been related to tumor volume, and has been useful for clinical follow-up. Secondly, we reviewed major chemotherapy previously described for malignant mesothelioma. The total response rate was 469 of 2,493 cases (18.8%). The response rates with single agent chemotherapy, combination chemotherapy, intraperitoneal or intracavitary chemotherapy, continuous hyperthermic peritoneal perfusion chemotherapy, and immunochemotherapy were 150 of 1,146 cases (13.1%), 209 of 1,019 cases (20.5%), 63 of 133 cases (47.4%), 11 of 13 cases (84.6%), and 36 of 182 cases (19.8%), respectively. Direct exposure of antitumor agent to the peritoneal surface is considered to be most effective against malignant peritoneal mesothelioma.
authors.affiliation: Department of Surgery, Wakayama Rosai Hospital, Wakayama, Japan. hotta@naxnet.or.jp
authors.forename: Tsukasa
authors.initials: T
authors.lastname: Hotta
authors.forename: Katsutoshi
authors.initials: K
authors.lastname: Taniguchi
authors.forename: Yasuhito
authors.initials: Y
authors.lastname: Kobayashi
authors.forename: Kiyofumi
authors.initials: K
authors.lastname: Johata
authors.forename: Masaki
authors.initials: M
authors.lastname: Sahara
authors.forename: Teiji
authors.initials: T
authors.lastname: Naka
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tanimura
authors.forename: Yukari T
authors.initials: YT
authors.lastname: Tsubota
mesh_terms: D000903:Antibiotics, Antineoplastic / Q000008:administration & dosage; D000964:Antimetabolites, Antineoplastic / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D006820:Hyaluronic Acid / Q000097:blood*; D008297:Male; D008654:Mesothelioma / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D016685:Mitomycin / Q000008:administration & dosage; D010534:Peritoneal Neoplasms / Q000097:blood* / Q000000981:diagnostic imaging / Q000188:drug therapy* / Q000473:pathology; D014057:Tomography, X-Ray Computed
chemical_list: D000903:Antibiotics, Antineoplastic; D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D016685:Mitomycin; D006820:Hyaluronic Acid; D002945:Cisplatin; D005472:Fluorouracil